patients with EC or AH who received MPA therapy at Tokushima University Hospital, Tokushima, Japan. The frequency of pregnancy and live births among the patients with EC or AH who received conservative treatment, followed by fertility treatment, were analyzed retrospectively.
Outcome: Twelve patients underwent fertility examinations and received fertility treatment immediately after the completion of conservative treatment for EC or AH.
One patient had the complication of severe diabetes and total embryo cryopreservation was performed before her diabetes was treated. Among the other 11 patients, 8 (72.7%) became pregnant at least once and 6 (54.5%) experienced at least 1 live birth.
Three patients (25.0%) suffered disease recurrence during or after the infertility treatment and all of the recurrences occurred in the EC cohort.
Conclusion:
When patients with EC or AH wish to preserve their fertility, it is recommended that prompt and effective fertility treatment, including assisted reproductive technology, should be initiated just after conservative treatment because EC and AH exhibit relatively high recurrence rates among conservatively treated patients.
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| INTRODUC TI ON
It has been reported that ~5%-25% of cases of endometrial carcinoma (EC) or atypical endometrial hyperplasia (AH) occur in women aged <40 years. [1] [2] [3] Essentially, the standard treatment for EC and AH is a total hysterectomy 4 ; however, conservative treatment with high-dose medroxyprogesterone acetate (MPA) is administered to women with EC or AH who wish to preserve their fertility (after adequate informed consent has been obtained). The regression rates that are associated with conservative treatment range from 70% to 80%; thus, it seems to be a feasible approach for EC and AH.
However, it also has been reported that ~30% of patients suffer a recurrence after the achievement of a complete response (CR). 5, 6 In addition, most patients with EC or AH have disease-associated ovulation disorders. Therefore, prompt and effective fertility treatment should be initiated just after conservative treatment in patients with EC or AH who wish to get pregnant immediately. The authors recommend that such patients should undergo fertility examinations and treatment as soon as possible after MPA therapy. Various studies have reported successful deliveries after conservative treatment. [5] [6] [7] [8] [9] [10] [11] [12] In addition, some studies have indicated that fertility treatment after conservative treatment for EC or AH results in better pregnancy outcomes, compared with expectant management [5] [6] [7] [8] [9] [10] ; however, the sample sizes of these studies were small and the accumulation of further studies is needed in order to allow firm conclusions to be drawn. Here is reported the pregnancy outcomes of patients with EC or AH that underwent MPA therapy, followed by fertility treatment at Tokushima University Hospital, Tokushima, Japan.
| C A S E REP ORTS
The Institutional Review Board of Tokushima University, Tokushima, Japan, approved this retrospective study (approval no.: #2814). The clinical and pregnancy outcomes of the patients that had been diag- 
| D ISCUSS I ON
As mentioned above, some studies have suggested that administering fertility treatment after conservative treatment improves the pregnancy outcomes of patients with EC or AH. [5] [6] [7] [8] [9] [10] For example, 1 study found that the live birth rate of patients who received fertility treatment was 39.4%, whereas that of patients who tried to spontaneously conceive was 14.9%. 5 Similarly, another study showed that 11 out of 20 patients conceived after conservative treatment and 10 out of these 11 patients received fertility treatment. 6 However, as far as the authors know, there is no consistent evidence about which kinds of fertility treatment are most advantageous after conservative treatment for EC and AH, although some studies have suggested that ART is especially beneficial for such patients. [8] [9] [10] For instance, 1 group reported that the pregnancy rate that is associated with ART is as high as 80% among conservatively treated patients with EC or AH. 10 As noted above, 72.7% of this study's patients were able to conceive after fertility treatment, indicating that the pregnancy rate at the current institution was equal to or greater than those that have been reported in previous studies. It should be noted that although the sample size of the present study was small, all of the patients that received ART conceived and delivered at least 1 child. In contrast, the primary disease relapsed in 25% of these patients and this recurrence rate was similar to those that have been described in previous studies. 5, 6 Therefore, it is recommended that prompt and effective fertility treatment, including ART, should be initiated just after conservative treatment in patients with EC or AH who want to become pregnant. In addition, the relatively high recurrence rate of EC and AH always must be taken into account when conservative treatment is considered.
TA B L E 1 Reproductive outcomes of fertility treatments for patient received conservative treatment AH, atypical hyperplasia; CC, clomiphene citrate; CR, complete response; DM, diabetes mellitus; EC, endometrial carcinoma; ET, embryo transfer; hMG, human menopausal gonadotropin; ICSI, intracytoplasmic sperm injection; IUI, intrauterine insemination; IVF, in vitro fertilization; MPA, medroxyprogesterone acetate; OHSS, ovarian hyperstimulation syndrome; PCOS, polycystic ovary syndrome; PR, partial response; rFSH, recombinant follicle-stimulating hormone.
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